TY - JOUR
AU - Lipworth, Brian J.
AU - Chan, Rory
AU - Misirovs, Rashad
PY - 2021
DA - December
TI - High-dose budesonide for early COVID-19
JO - The Lancet
EP - 2147
VL - 398
IS - 10317
DO - https://doi.org/10.1016/S0140-6736(21)02440-5
AB - We were encouraged by the results of the PRINCIPLE trial,which in vulnerable individuals showed inhaled budesonide to confer a non-significant –25% (95% CI –45 to 3) relative reduction in the composite coprimary endpoint of hospital admission or death, with the number needed to treat being 50.Notably, the study had 90% power to detect a 50% reduction in the composite endpoint. The investigators appear to have attributed any protective effects of budesonide to its local glucocorticoid activity in the lung.
PB - Elsevier
UR - https://discovery.dundee.ac.uk/en/publications/3c7230c3-d677-452f-8f40-0d933171d260
KW - Coronavirus (COVID-19)
ER